FDA Authorizes New Quest Diagnostics Method for Covid-19 Tests

July 29, 2020, 8:15 PM

Quest Diagnosticssaid the FDA has granted emergency use authorization (EUA) for a new laboratory technique that speeds the process of extracting viral RNA from specimens and will enable the company to expand its daily capacity of Covid-19 molecular diagnostic tests on behalf of patients in the U.S.

  • With the new FDA EUA, five of the company’s laboratories in the U.S. may now run this new RNA extraction method, including on pooled specimens.
  • Those laboratories are well situated geographically to address high testing demand in states where the virus has been surging. The labs are in San Juan Capistrano and Valencia,...

To read the full article log in.

Learn more about a Bloomberg Law subscription.